Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.
Osteoporos Int. 2015 Nov;26(11):2561-72. doi: 10.1007/s00198-015-3250-7. Epub 2015 Jul 21. In particular, we discuss the close relationship between PBMs and osteoclasts, and highlight the utility of PBMs in study the pathophysiological mechanisms underlying various skeletal … Leer más
Overall, in addition to the weight loss promoting properties of calcium, on its own or co-supplemented with conjugated linoleic acid, our results support beneficial effects on bone metabolism in mice.
J Clin Endocrinol Metab. 2015 Nov;100(11):4208-14. doi: 10.1210/jc.2015-2829. Epub 2015 Sep 10 CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone … Leer más
Our results suggest that serum levels of myostatin and irisin are related in patients with type 2 diabetes. Triglyceride and glucose levels could modulate myostatin and irisin concentrations as a compensatory mechanism to improve the … Leer más
J Bone Miner Res. 2015 Oct;30(10):1758-66. doi: 10.1002/jbmr.2515. Epub 2015 May 10. In summary, for older men and women, calcium intakes of up to 1348 (316) mg/d from food were associated with decreased risks for … Leer más
Osteoporos Int. 2015 Oct 28. [Epub ahead of print] Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without … Leer más
Sclerostin and estradiol levels are associated with the response to bisphosphonate therapy in women with postmenopausal osteoporosis.
Curr Osteoporos Rep. 2015 Oct;13(5):287-301. doi: 10.1007/s11914-015-0282-z. Among women 50-64 years old, a Fracture Risk Assessment Tool (FRAX) threshold ≥9.3 % had a sensitivity of 33 % for identifying BMD T-score ≤-2.5 and 26 % … Leer más
The application of the NOGG and NOF guidelines led to a decrease in BMD indications, reducing costs and improving efficiency in the diagnostic management of osteoporosis, although variability exists between the guidelines.
